Story perspectives

Trump Orders FDA to Fast-Track Psychedelics, Allocates $50 M

4/23/2026

Summary

Story summary

U.S. President Donald Trump signed an order directing FDA to accelerate psychedelic reviews and earmarking $50 million for research.
AtaiBeckley rose over 30% and Enveric BioSciences climbed over 140% after the order, prompting analysts to say it validates psychedelics and lowers regulatory risk.
Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan and FDA Commissioner Marty Makary attended, noting reviews could start by summer 2026 and cut approval to one-to-two months.

1 of 1

Story summary

U.S. President Donald Trump signed an order directing FDA to accelerate psychedelic reviews and earmarking $50 million for research.
AtaiBeckley rose over 30% and Enveric BioSciences climbed over 140% after the order, prompting analysts to say it validates psychedelics and lowers regulatory risk.
Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan and FDA Commissioner Marty Makary attended, noting reviews could start by summer 2026 and cut approval to one-to-two months.